This study is accepting new patients by invitation only

Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis

a study on Atopic Dermatitis (Eczema)

Summary

Eligibility
for people ages 18-75 (full criteria)
Location
at Los Angeles, California and other locations
Dates
study started
study ends around

Description

Summary

The purpose of this study is to evaluate the safety and efficacy of long-term treatment with IMG-007 in participants with moderate-to-severe atopic dermatitis (AD)

Official Title

A Long-term Extension Study to Evaluate the Safety and Efficacy of Subcutaneous IMG-007 in Participants of a Previous IMG-007 Moderate-To-Severe Atopic Dermatitis Clinical Trial

Keywords

Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema, IMG-007, Dermatitis, Atopic, Dermatitis, Skin Diseases, Immune System Diseases, Dermatologic Agents

Eligibility

For people ages 18-75

Enrolling by invitation participants with moderate to severe AD who have completed IMG-007-203

Locations

  • Inmagene Site 23
    Los Angeles California 90095 United States
  • Inmagene Site 1
    Lancaster California 93534 United States

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
Inmagene LLC
ID
NCT07734415
Phase
Phase 2 Atopic Dermatitis (Eczema) Research Study
Study Type
Interventional
Participants
Expecting 400 study participants
Last Updated